Merz North America officially opens new HQ
RALEIGH, N.C. – Merz North America on Thursday announced the official opening of its new headquarters in Raleigh, N.C. North Carolina Governor Pat McCrory was present at the event to officiate at the ribbon cutting ceremony and formally welcome Merz to the Triangle business community.
“By centralizing their North American operations in Raleigh, Merz has reaffirmed their commitment to North Carolina and their belief that this is a great place to do business,“ McCrory said. “Merz is a family-owned company with a strong focus on growth and innovation, and North Carolina’s talented workforce and thriving business climate will help them to achieve even greater success.“
“The opening of our new headquarters is a key moment in Merz North America’s success story. Our progress over the past three years has been fueled by significant internal success and execution, as well as two recent strategic acquisitions,“ said Bill Humphries, president and CEO of Merz North America. “Now, as a result of our move to Raleigh, we are able house all of our core business functions in one place, giving us the opportunity to become an even more significant player in our industry.“
Merz first established its U.S. presence in 1995. Prior to their move to Raleigh in January 2015, Merz North America was based in Greensboro, N.C. from 1995 to 2014.
Start-up seeks capital for fish-friendly hemp oil omega supplement
VANCOUVER, British Columbia – In an effort to help save the world’s fish population, a new company on Thursday launched a healthy and fish-friendly alternative to fish oil. Envision Naturals has created a hemp seed oil in soft gel form that provides consumers with the omega essential fatty acids they require for a proper diet.
Envision Naturals, in an effort to increase awareness for their product and raise some initial capital, has launched a KickStarter campaign that will run through July 3 with the goal of raising $75,000 Canadian ($59,800 U.S.) to finance the first production run.
“It is about providing an environmentally friendly, healthy product that will help people,” said Chris Dollard, co-founder of Envision Naturals. “The growing awareness of the importance of omega EFAs has led to an explosion in their consumption but this explosion is not without its risks. It is our goal to mitigate these risks to the environment and provide people with an alternative that gives them the Omega EFAs they require.”
“We realized something needed to be done and figured there had to be an alternative,” said Anton Mattadeen, co-founder of Envision Naturals. “We partnered with a researcher at the University of BC and realized that hemp could provide that solution.”
Hemp, which the company is quick to point out is not marijuana, is made from cold-pressed hemp seeds and is considered to be a good source of EFAs for the human body. It is vegan-friendly, and is certified organic by Pro-Cert Organic Systems, certified Kosher by the Orthodox Union and certified Halal by the Halal Product Development Services, Envision Naturals reported.
Cardinal Health enhances generic sourcing in blockbuster deal
DUBLIN, Ohio – Cardinal Health on Friday announced plans to acquire The Harvard Drug Group, a distributor of generic pharmaceuticals, over-the-counter medications and related products to retail, institutional and alternate care customers, in a deal worth $1.1 billion.
The deal on the outset enhances Cardinal's generic pharmaceutical distribution business. In addition, the acquisition of The Harvard Drug Group gives Cardinal a broader portfolio of OTC products and expands Cardinal Health's existing telesales programs, the wholesaler stated.
"The Harvard Drug Group aligns perfectly with our commitment to provide the most comprehensive line of pharmaceutical products for the broadest range of customers," stated George Barrett, chairman and CEO Cardinal Health. "This acquisition enhances our ability to support retail and institutional customers and further utilizes Red Oak, our joint venture with CVS Health to source generics."
Headquartered in Livonia, Mich., The Harvard Drug Group had revenues of approximately $450 million in 2014. The transaction is expected to close in the beginning of fiscal year 2016 subject to regulatory approvals and other customary closing conditions.
The Harvard Drug Group is currently owned by Court Square Capital Partners.
Loading Post Please Wait...